Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Phase 2 entities : Eli lilly and company save search
Innovent Announces Publication of Mazdutide (IBI362) Phase 2 Full Results in Chinese Patients with Type 2 Diabetes in Diabetes Care
Published: 2023-11-22 (Crawled : 05:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: -0.74%
H: 0.71%
C: 0.71%
LLY | News | $745.69 1.96% -0.16% 2M
|
Health Technology
|
| O: -0.44%
H: 0.63%
C: -0.05%
SNY | News | $47.69 1.15% 1.13% 1.7M
|
Health Technology
|
| O: -0.34%
H: 0.0%
C: 0.0%
ibi362 publication care chinese diabetes results phase 2
Innovent Announces First Participant Dosed in the Higher-dose Cohort of a Phase 2 Clinical Trial of Mazdutide in Chinese Adults with Obesity
Published: 2022-09-05 (Crawled : 01:00) - prnewswire.com
LLY | News | $745.69 1.96% -0.16% 2M
|
Health Technology
| Email alert
Add to watchlist
INCY | $51.62 -0.58% -0.58% 2.5M
|
Health Technology
| Email alert
Add to watchlist
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
| Email alert
Add to watchlist
SNY | News | $47.69 1.15% 1.13% 1.7M
|
Health Technology
| Email alert
Add to watchlist
obesity chinese trial phase 2
ALX Oncology Announces First Patient Dosed in Phase 2 Investigator-Sponsored Trial of Evorpacept in Combination with Cetuximab and Pembrolizumab in Patients with Advanced Colorectal Cancer
Published: 2022-08-11 (Crawled : 16:00) - biospace.com/
LLY | News | $745.69 1.96% -0.16% 2M
|
Health Technology
|
| O: -1.18%
H: 1.46%
C: 0.05%
ALXO M | $15.5 8.92% 8.19% 440K
|
Commercial Services
|
| O: 2.97%
H: 6.15%
C: -1.44%
trial cancer phase 2
Innovent Announces Phase 2 Clinical Study of Picankibart (IBI112) in Chinese Patients with Moderate-to-severe Plaque Psoriasis Met Primary Endpoint
Published: 2022-08-10 (Crawled : 01:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: -6.43%
H: 0.0%
C: -6.31%
LLY | News | $745.69 1.96% -0.16% 2M
|
Health Technology
|
| O: 0.49%
H: 0.86%
C: 0.04%
SNY | News | $47.69 1.15% 1.13% 1.7M
|
Health Technology
|
| O: -4.06%
H: 0.0%
C: 0.0%
INCY | $51.62 -0.58% -0.58% 2.5M
|
Health Technology
|
| O: 1.13%
H: 0.52%
C: -0.58%
ibi112 chinese psoriasis study plague phase 2
Significant Glycemic Control and Weight Loss: Innovent Announces Phase 2 Study of Mazdutide (IBI362) in Chinese Patients with Type 2 Diabetes Met Primary Endpoint
Published: 2022-07-19 (Crawled : 01:00) - prnewswire.com
LLY | News | $745.69 1.96% -0.16% 2M
|
Health Technology
|
| O: 0.72%
H: 1.02%
C: 0.65%
INCY | $51.62 -0.58% -0.58% 2.5M
|
Health Technology
|
| O: -0.83%
H: 0.0%
C: 0.0%
ibi362 chinese control diabetes study phase 2
Innovent Announces First Patient Dosed in a Phase 2 Clinical study of IBI112 (IL-23p19 Monoclonal Antibody) in Patients with Moderate-to-Severe Active Ulcerative Colitis
Published: 2022-07-04 (Crawled : 01:00) - prnewswire.com
INCY | $51.62 -0.58% -0.58% 2.5M
|
Health Technology
| Email alert
Add to watchlist
LLY | News | $745.69 1.96% -0.16% 2M
|
Health Technology
| Email alert
Add to watchlist
ibi112 active study phase 2 ulcerative colitis
Sermonix Pharmaceuticals’ Phase 2 Lasofoxifene Trial Poster Receives a GRASP Advocate Choice Award, Selected for Post-ASCO Patient Advocate Investigator Discussions
Published: 2022-06-08 (Crawled : 15:00) - biospace.com/
LLY | News | $745.69 1.96% -0.16% 2M
|
Health Technology
|
| O: 3.02%
H: 0.98%
C: 0.34%
LGND | $69.97 2.1% 2.06% 140K
|
Health Technology
|
| O: -1.26%
H: 1.8%
C: -0.71%
trial phase 2
Innovent Announces Phase 2 study of Mazdutide（IBI362） in Chinese Participants with Overweight or Obesity Met Primary and All Key Secondary Endpoints
Published: 2022-06-08 (Crawled : 01:00) - prnewswire.com
LLY | News | $745.69 1.96% -0.16% 2M
|
Health Technology
|
| O: 3.02%
H: 0.98%
C: 0.34%
INCY | $51.62 -0.58% -0.58% 2.5M
|
Health Technology
|
| O: 1.5%
H: 1.13%
C: -0.01%
ibi362 obesity chinese phase 2
Innovent and AnHeart Jointly Present Updated Phase 2 Efficacy and Safety Data of Taletrectinib (ROS1-TKI) at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
Published: 2022-06-07 (Crawled : 01:00) - prnewswire.com
LLY | News | $745.69 1.96% -0.16% 2M
|
Health Technology
|
| O: -3.62%
H: 0.0%
C: 0.0%
INCY | $51.62 -0.58% -0.58% 2.5M
|
Health Technology
|
| O: -0.89%
H: 0.0%
C: 0.0%
phase 2
AnHeart Therapeutics and Innovent Biologics Present Updated Phase 2 Efficacy and Safety Data of Taletrectinib (ROS1 Inhibitor) at ASCO 2022
Published: 2022-06-06 (Crawled : 16:00) - biospace.com/
LLY | News | $745.69 1.96% -0.16% 2M
|
Health Technology
|
| O: 3.83%
H: 0.0%
C: 0.0%
INCY | $51.62 -0.58% -0.58% 2.5M
|
Health Technology
|
| O: 0.01%
H: 0.0%
C: 0.0%
therapeutics asco phase 2
Veru Announces Oral Late-Breaking Presentation of Phase 2 Data of Sabizabulin for the Treatment of Hospitalized Severe COVID-19 Patients
Published: 2022-04-25 (Crawled : 14:00) - biospace.com/
LLY | News | $745.69 1.96% -0.16% 2M
|
Health Technology
|
| O: -3.29%
H: 2.58%
C: 2.31%
VERU | $1.27 0.0% 2.6M
|
Health Technology
|
| O: 0.89%
H: 27.06%
C: 24.67%
covid-19 treatment sabizabulin presentation phase 2
Rigel Announces Publication of Data from Phase 2 Clinical Study of Fostamatinib for the Treatment of Warm Antibody Autoimmune Hemolytic Anemia in the American Journal of Hematology
Published: 2022-03-08 (Crawled : 13:30) - prnewswire.com
LLY | News | $745.69 1.96% -0.16% 2M
|
Health Technology
|
| O: -0.38%
H: 0.0%
C: 0.0%
RIGL | $1.135 0.44% 0.44% 520K
|
Health Technology
|
| O: -1.78%
H: 8.93%
C: 3.63%
america treatment ema phase 2 anemia antibody
ALX Oncology Announces First Patient Dosed in ASPEN-06, a Phase 2/3 Study of Evorpacept for the Treatment of Patients with Advanced Gastric or Gastroesophageal Junction CancerPhase 2/3 study initiated in collaboration with Eli Lilly and Company
Published: 2022-03-02 (Crawled : 18:00) - biospace.com/
LLY | News | $745.69 1.96% -0.16% 2M
|
Health Technology
|
| O: 0.79%
H: 0.0%
C: 0.0%
ALXO M | $15.5 8.92% 8.19% 440K
|
Commercial Services
|
| O: 0.0%
H: 4.13%
C: 3.97%
aspen-06 treatment phase 2 phase 2/3 collaboration cancer initiated
Innovent Announces Pivotal Phase 2 Results for Parsaclisib (PI3Kδ inhibitor) Presented at ASH 2021 Show Durable Responses in Patients with Relapsed or Refractory Follicular Lymphoma
Published: 2021-12-14 (Crawled : 01:00) - prnewswire.com
LLY | News | $745.69 1.96% -0.16% 2M
|
Health Technology
|
| O: 0.82%
H: 0.92%
C: 0.66%
INCY | $51.62 -0.58% -0.58% 2.5M
|
Health Technology
|
| O: 3.76%
H: 3.79%
C: 1.89%
phase 2 phase 2 results results
Neurimmune and TVM Capital Life Science Announce the Initiation of AL-S Pharma's Phase 2 Study of AP-101 for the Treatment of ALS
Published: 2021-11-18 (Crawled : 21:00) - biospace.com/
LLY | News | $745.69 1.96% -0.16% 2M
|
Health Technology
|
| O: 2.14%
H: 0.69%
C: -0.26%
treatment phase 2 life science als
At Week 104, 75% of Patients with Ulcerative Colitis Taking Mirikizumab Maintained Symptomatic Remission in Phase 2 Study
Published: 2021-10-01 (Crawled : 14:00) - biospace.com/
LLY | News | $745.69 1.96% -0.16% 2M
|
Health Technology
|
| O: 0.12%
H: 0.0%
C: 0.0%
phase 2 ulcerative colitis
Innovent and AnHeart Announce Interim Data from Phase 2 Trial of Taletrectinib in ROS1-Positive NSCLC at the CSCO 2021 Annual Meeting
Published: 2021-09-27 (Crawled : 00:00) - prnewswire.com
LLY | News | $745.69 1.96% -0.16% 2M
|
Health Technology
|
| O: -1.21%
H: 0.47%
C: -1.55%
INCY | $51.62 -0.58% -0.58% 2.5M
|
Health Technology
|
| O: -0.89%
H: 0.54%
C: 0.51%
phase 2 heart positive trial
Innovent Announces First Patient Dosed in a Phase 2 Clinical Trial of IBI112 (IL-23 Monoclonal Antibody) in Patients with Moderate-to-severe Plaque Psoriasis
Published: 2021-09-24 (Crawled : 00:00) - prnewswire.com
LLY | News | $745.69 1.96% -0.16% 2M
|
Health Technology
|
| O: 0.26%
H: 0.0%
C: 0.0%
INCY | $51.62 -0.58% -0.58% 2.5M
|
Health Technology
|
| O: -0.36%
H: 0.0%
C: 0.0%
phase 2 antibody trial psoriasis plague
Innovent Releases Phase 2 Results of Pemigatinib in Chinese Patients with Advanced Cholangiocarcinoma at ESMO Congress 2021
Published: 2021-09-17 (Crawled : 01:00) - prnewswire.com
LLY | News | $745.69 1.96% -0.16% 2M
|
Health Technology
|
| O: -0.54%
H: 0.0%
C: 0.0%
INCY | $51.62 -0.58% -0.58% 2.5M
|
Health Technology
|
| O: 0.04%
H: 0.0%
C: 0.0%
chinese phase 2 phase 2 results results
Innovent Announces First Patient with Type 2 Diabetes Dosed in a Phase 2 Clinical Trial of IBI362 (a GLP-1R and Glucagon Receptor Dual Agonist) in China
Published: 2021-09-08 (Crawled : 00:00) - prnewswire.com
LLY | News | $745.69 1.96% -0.16% 2M
|
Health Technology
|
| O: -0.08%
H: 0.44%
C: 0.09%
diabetes phase 2 china trial
Gainers vs Losers
| 78% | 22% |
Top 10 Gainers
MTTR | News 4 | $4.6 164.37% 62.17% 28M
|
AGBA | $2.94 135.2% 57.48% 66M
|
Finance
EDBL | News | $6.46 71.81% 41.8% 2M
|
MTC | $2.25 44.23% 30.67% 6M
|
Technology Services
OPRT | News | $3.175 41.11% 29.13% 12M
|
Finance
SHIM | $3.05 35.56% 26.23% 1.1M
|
HKIT | $1.345 31.86% 24.16% 390K
|
Technology Services
ABVC | $1.36 30.77% 23.53% 7.4M
|
Wholesale Trade
OST | $0.512 28.0% 21.88% 290K
|
POET | $1.59 27.2% 21.38% 4.2M
|
Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.